Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2025-06-11 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
科创板上市公司独立董事提名人声明与承诺-高国垒
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the board of a listed company on the Science and Technology Innovation Board (科创板). It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There is no financial data, no report of voting results, no announcement of a meeting, nor any financial performance or management discussion. The document is a declaration related to board/management matters, specifically about the nomination of a board member. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-06-11 Chinese
《对外投资决策制度》（2025年6月修订）
Governance Information Classification · 95% confidence The document is titled '对外投资决策制度' which translates to 'External Investment Decision System' and details the company's internal policies and procedures for managing external investments, including approval authorities, responsibilities, controls, and disclosure requirements. It is a governance or policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit results, or voting results. It is not a presentation or transcript. It is a formal internal governance document outlining decision-making and control processes related to investments. Therefore, it fits best under Governance Information (CGR). The document length (5583 characters) and content confirm it is a substantive policy document, not a brief announcement or certification.
2025-06-11 Chinese
科创板上市公司独立董事提名人声明与承诺-吴丹枫
Regulatory Filings Classification · 95% confidence The document is a formal statement and commitment by a nominator and the board of a Shanghai-listed company regarding the nomination of an independent director candidate. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report of financial performance, no voting results, no management changes, no earnings or capital updates, and no legal proceedings. The document is a regulatory compliance statement related to board nominations, not a report or announcement of financial or corporate events. It fits best under Regulatory Filings (RNS) as a compliance declaration that does not fit other specific categories.
2025-06-11 Chinese
关于召开2025年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 second extraordinary general meeting of shareholders (临时股东大会) for the company 和元生物技术（上海）股份有限公司. It includes information about the meeting date, voting methods, agenda items including board elections and governance amendments, instructions for shareholders on voting and attendance, and attachments such as proxy forms and explanations of cumulative voting. There is no financial data or results reported, nor is it a transcript or presentation. It is a formal announcement of a shareholders meeting with detailed agenda and procedural information. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or other shareholder meetings. The document is over 5,000 characters and contains substantive meeting details, not just a brief announcement or regulatory filing. Therefore, the classification is AGM-R with high confidence.
2025-06-11 Chinese
《内部审计制度》（2025年6月修订）
Audit Report / Information Classification · 95% confidence The document is titled '内部审计制度' (Internal Audit System) of 和元生物技术（上海）股份有限公司 and details the internal audit policies, responsibilities, organizational structure, and procedures within the company. It extensively covers internal audit functions, audit committee roles, internal control evaluations, and compliance with laws and regulations. There is no indication that this is an annual report, earnings release, or any other financial statement. It is not a brief announcement or a certification but a detailed internal audit policy document. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to internal controls and audit functions, excluding full annual reports. The document length (7164 characters) and content confirm it is a substantive internal audit policy document rather than a mere announcement or regulatory filing. FY 2025
2025-06-11 Chinese
《募集资金管理制度》（2025年6月修订）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, use, storage, and supervision of funds raised by the company through securities issuance. It extensively references regulatory requirements and internal company rules regarding the use of raised funds, including cash management, project investment, and reporting obligations. The document is a policy or procedural manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, voting results, or management changes. It is not a report publication announcement or a certification. The content is focused on the management and regulatory compliance of capital raised by the company, which aligns with the category 'Capital/Financing Update (CAP)' as it relates to the management and use of fundraising proceeds. Therefore, the most appropriate classification is CAP with high confidence.
2025-06-11 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.